ATE439379T1 - Chimärer antagonist anth1 - Google Patents

Chimärer antagonist anth1

Info

Publication number
ATE439379T1
ATE439379T1 AT03720120T AT03720120T ATE439379T1 AT E439379 T1 ATE439379 T1 AT E439379T1 AT 03720120 T AT03720120 T AT 03720120T AT 03720120 T AT03720120 T AT 03720120T AT E439379 T1 ATE439379 T1 AT E439379T1
Authority
AT
Austria
Prior art keywords
anth1
chimeric antagonist
antagonist
chimeric
antagonist anth1
Prior art date
Application number
AT03720120T
Other languages
English (en)
Inventor
Rivero Iraldo Bello
Ruiz Yeny Torres
Garces Elizabeth Blanco
Roll Giselle Penton
Saura Pedro Lopez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Application granted granted Critical
Publication of ATE439379T1 publication Critical patent/ATE439379T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
AT03720120T 2002-05-10 2003-05-08 Chimärer antagonist anth1 ATE439379T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20020095A CU23229A1 (es) 2002-05-10 2002-05-10 ANTAGONISTA QUIMéRICO ANTH1
PCT/CU2003/000006 WO2003095488A1 (es) 2002-05-10 2003-05-08 Antagonista quimérico anth1

Publications (1)

Publication Number Publication Date
ATE439379T1 true ATE439379T1 (de) 2009-08-15

Family

ID=40091620

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03720120T ATE439379T1 (de) 2002-05-10 2003-05-08 Chimärer antagonist anth1

Country Status (17)

Country Link
US (2) US7429384B2 (de)
EP (1) EP1550672B1 (de)
JP (1) JP4275065B2 (de)
KR (1) KR20040108786A (de)
CN (1) CN100384873C (de)
AR (1) AR039973A1 (de)
AT (1) ATE439379T1 (de)
AU (1) AU2003223832B2 (de)
BR (1) BR0304827A (de)
CA (1) CA2485439A1 (de)
CU (1) CU23229A1 (de)
DE (1) DE60328807D1 (de)
MX (1) MXPA04011143A (de)
RU (1) RU2322455C2 (de)
UA (1) UA81908C2 (de)
WO (1) WO2003095488A1 (de)
ZA (1) ZA200409073B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2758023A1 (en) * 2008-04-09 2009-10-15 Cornell University Commensal bacteria as signal mediators within a mammalian host
CA2814698A1 (en) 2010-10-15 2012-04-19 Cornell University Compositions and methods for treating endocrine, gastrointestinal or autoimmune disorders
KR20210018955A (ko) * 2013-05-08 2021-02-18 종이앤 장 특정 탈수초화 및 수초형성부전-기초 장애를 치료하고/하거나 재수초화를 촉진하는 방법
CN107266586A (zh) * 2017-08-09 2017-10-20 安徽九川生物科技有限公司 一种重组猪长效干扰素γ及制备此长效干扰素γ的融合蛋白及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393502B1 (de) * 1989-04-19 1995-12-27 F. Hoffmann-La Roche Ag Auflösbare Interferon-gamma-Rezeptoren sowie Verfahren zu deren Herstellung
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
CA2114168A1 (en) * 1993-03-05 1994-09-06 Zlatko Dembic Chimeric human interferon-gamma-receptor/immunoglobulin polypeptides
AU696560B2 (en) * 1993-03-19 1998-09-10 Fred D. Finkelman Pharmaceutical compositions comprising a ligand complexed with a soluble receptor
EP0621338A3 (de) 1993-04-21 1997-10-29 Ajinomoto Kk Die Interleukin-2 Antwort blockierende Immunsuppressor.

Also Published As

Publication number Publication date
AR039973A1 (es) 2005-03-09
RU2322455C2 (ru) 2008-04-20
UA81908C2 (uk) 2008-02-25
US20060073115A1 (en) 2006-04-06
RU2004136170A (ru) 2005-05-27
AU2003223832A1 (en) 2003-11-11
CA2485439A1 (en) 2003-11-20
CN100384873C (zh) 2008-04-30
JP4275065B2 (ja) 2009-06-10
CN1662555A (zh) 2005-08-31
MXPA04011143A (es) 2005-01-25
EP1550672A1 (de) 2005-07-06
ZA200409073B (en) 2005-05-09
US7429384B2 (en) 2008-09-30
US20070160575A1 (en) 2007-07-12
DE60328807D1 (de) 2009-09-24
EP1550672B1 (de) 2009-08-12
BR0304827A (pt) 2004-08-17
CU23229A1 (es) 2007-09-26
WO2003095488A1 (es) 2003-11-20
AU2003223832B2 (en) 2009-02-19
JP2006506958A (ja) 2006-03-02
KR20040108786A (ko) 2004-12-24

Similar Documents

Publication Publication Date Title
ATE457980T1 (de) Aryloxime
ATE534648T1 (de) C-6-modifizierte indazolylpyrrolotriazine
ATE318817T1 (de) Aza-arylpiperazine
ATE427876T1 (de) Luftkissenboot
NO20044046L (no) Substituerte hydroksyetylaminer
DE60326590D1 (de) Tend lamotrigin
ATE349458T1 (de) Etonogestrelester
ATE356124T1 (de) Hydroxyalkylsubstituierte pyrido-7-pyrimidin-7- one
ATE496887T1 (de) Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
ATA1572002A (de) Managementspleisskassette
ATE444953T1 (de) Substituierte spirobenzazepine
ATA4142004A (de) Trägerverbau
ATE469773T1 (de) Zugöse
ATE439379T1 (de) Chimärer antagonist anth1
ATA19152002A (de) Hubkupplung
ATE396192T1 (de) N-sulfonylaminothiazole
ITMI20030948A1 (it) Portalampada
DE50306228D1 (de) Substituierte benzdioxepine
DE10360313A8 (de) Schweißvorrichtung
FR2840006B1 (fr) Construction demontable
DE10244834B8 (de) Suszeptometer
DE50209283D1 (de) Tropfbewässerungsrohr
ATA16872002A (de) Zwischenstück
DE50203335D1 (de) Falzschwertantriebsvorrichtung
ATA8092002A (de) Pibf

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties